Compound and method for treating diseases and disorders

Abstract

Described is a cannabinoid-terpenoid solution (CTS) and method of treating a disease state or condition in animals other than humans via cannabinoid-terpenoid therapy. The CTS includes a unique combination of cannabinoids, terpenoids (terpenes), and a lipophilic carrier to allow safely and effectively treat the animal.

What is claimed is: 
     
         1 . A cannabinoid-terpenoid solution (CTS) for use in the administration of a cannabinoid-terpenoid medicament in a mammal, comprising:
 two or more cannabinoids; and   one or more terpenes.   
     
     
         2 . The cannabinoid-terpenoid solution as set forth in  claim 1 , wherein the two or more cannabinoids comprise at least two cannabinoids selected from a group consisting of cannabidiol (CBD), tetrahydrocannabinol (THC), cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), cannabidivarin (CBDV), cannabidiolic acid (CBDA), tetrahydrocannabivarin (THCV), and tetrahydrocannabinolic acid (THCA). 
     
     
         3 . The cannabinoid-terpenoid solution as set forth in  claim 2 , further comprising a lipophilic carrier mixed with the two or more cannabinoids and the one or more terpenes. 
     
     
         4 . The cannabinoid-terpenoid solution as set forth in  claim 3 , wherein the two or more cannabinoids collectively comprise an amount less than or equal to 50 percent of the CTS, wherein the one or more terpenes comprise an amount less than or equal to 60 percent of the CTS, and wherein the lipophilic carrier comprises an amount less than or equal to 85 percent of the CTS. 
     
     
         5 . The cannabinoid-terpenoid solution as set forth in  claim 2 , wherein the two or more cannabinoids comprise at least CBD and THC, and wherein the CBD comprises between 7 percent and 15 percent of the CTS and the THC comprises between 0.1 and 10 percent of the CTS, thereby forming a CBD dominant compound. 
     
     
         6 . The cannabinoid-terpenoid solution as set forth in  claim 5 , wherein the CBD comprises between 10 percent and 14 percent of the CTS and the THC comprises between 0.3 percent and 1 percent of the CTS, thereby forming a CBD dominant compound. 
     
     
         7 . The cannabinoid-terpenoid solution as set forth in  claim 5 , wherein the one or more terpenes comprise between 13 and 17 percent of the CTS. 
     
     
         8 . The cannabinoid-terpenoid solution as set forth in  claim 2 , wherein the two or more cannabinoids comprise at least CBD and THC, and wherein the CBD comprises between 7 percent and 30 percent of the CTS and the THC comprises between 1 and 10 percent of the CTS, thereby forming a CBD rich compound. 
     
     
         9 . The cannabinoid-terpenoid solution as set forth in  claim 8 , wherein the CBD comprises between 8 percent and 12 percent of the CTS and the THC comprises between 2 percent and 4 percent of the CTS, thereby forming a CBD rich compound. 
     
     
         10 . The cannabinoid-terpenoid solution as set forth in  claim 8 , wherein the one or more terpenes comprise between 16 and 20 percent of the CTS. 
     
     
         11 . The cannabinoid-terpenoid solution as set forth in  claim 2 , wherein the two or more cannabinoids comprise at least CBD and THC, and wherein the CBD comprises between 1 percent and 5 percent of the CTS and the THC comprises between 1 and 5 percent of the CTS, thereby forming a CBD:THC balanced compound. 
     
     
         12 . The cannabinoid-terpenoid solution as set forth in  claim 2 , wherein the two or more cannabinoids comprise at least CBD and THC, and wherein the THC comprises between 7 percent and 30 percent of the CTS and the CBD comprises between 1 and 10 percent of the CTS, thereby forming a THC rich compound. 
     
     
         13 . The cannabinoid-terpenoid solution as set forth in  claim 2 , wherein the two or more cannabinoids comprise at least CBD and THC, and wherein the THC comprises between 7 percent and 15 percent of the CTS and the CBD comprises between 0.2 and 10 percent of the CTS, thereby forming a THC dominant compound. 
     
     
         14 . The cannabinoid-terpenoid solution as set forth in  claim 13 , wherein the THC comprises between 10 percent and 14 percent of the CTS and the CBD comprises between 0.3 percent and 2 percent of the CTS, thereby forming a THC dominant compound. 
     
     
         15 . The cannabinoid-terpenoid solution as set forth in  claim 2 , wherein the lipophilic carrier is a medium chain triglyceride (MCT) oil. 
     
     
         16 . The cannabinoid-terpenoid solution as set forth in  claim 2 , wherein at least one of the two or more cannabinoids is a highly purified extract of cannabis which comprises at least 90% A9-tetrahydrocannabinol (THC). 
     
     
         17 . The cannabinoid-terpenoid solution as set forth in  claim 2 , wherein the two or more cannabinoids include CBD and THC, such that the CTS comprises less than 0.3% THC. 
     
     
         18 . A cannabinoid-terpenoid solution (CTS) for use in the administration of a cannabinoid-terpenoid medicament in a mammal, comprising:
 two or more cannabinoids, the two or more cannabinoids comprising at least two cannabinoids selected from a group consisting of cannabidiol (CBD), tetrahydrocannabinol (THC), cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), cannabidivarin (CBDV), cannabidiolic acid (CBDA), tetrahydrocannabivarin (THCV), and tetrahydrocannabinolic acid (THCA).   
     
     
         19 . The cannabinoid-terpenoid solution as set forth in  claim 18 , wherein the two or more cannabinoids include at least CBD and THC, such that CBD and THC are mixed within the CTS to form a ratio with respect to one another, the ratio being selected from a group consisting of CBD dominant, CBD rich, CBD:THC balanced, THC rich, and THC dominant. 
     
     
         20 . The cannabinoid-terpenoid solution as set forth in  claim 19 , further comprising one or more terpenes mixed with the two or more cannabinoids.